Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv 69978, Israel.
Genome Med. 2011 Oct 27;3(10):69. doi: 10.1186/gm285.
Informing patients about risks and benefits of alternative treatment options and choosing between them is becoming a bigger challenge as knowledge about the relationship between the individual's genetic profile and the efficacy and safety of available medications accumulates. Putting personalized medicine into practice requires new modes of information sharing and decision making by patient and physician. This is illustrated by a case study on treatment choices of breast cancer patients following genotyping for CYP2D6, recently published in Genome Medicine.See research article: http://genomemedicine.com/content/3/10/64.
随着关于个体基因谱与现有药物疗效和安全性之间关系的知识不断积累，向患者告知替代治疗方案的风险和益处并在其中进行选择正变得越来越具有挑战性。将个性化医学付诸实践需要患者和医生采用新的信息共享和决策模式。最近在《基因组医学》杂志上发表的一篇关于 CYP2D6 基因分型后乳腺癌患者治疗选择的病例研究说明了这一点。参见研究文章：http://genomemedicine.com/content/3/10/64。
